[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX363522B - Síntesis de productos peptídicos que contienen hidantoína. - Google Patents

Síntesis de productos peptídicos que contienen hidantoína.

Info

Publication number
MX363522B
MX363522B MX2015013464A MX2015013464A MX363522B MX 363522 B MX363522 B MX 363522B MX 2015013464 A MX2015013464 A MX 2015013464A MX 2015013464 A MX2015013464 A MX 2015013464A MX 363522 B MX363522 B MX 363522B
Authority
MX
Mexico
Prior art keywords
synthesis
peptide products
containing peptide
hydantoin
hydantoin containing
Prior art date
Application number
MX2015013464A
Other languages
English (en)
Other versions
MX2015013464A (es
Inventor
Henkel Bernd
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MX2015013464A publication Critical patent/MX2015013464A/es
Publication of MX363522B publication Critical patent/MX363522B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con un método para sintetizar un producto peptídico que comprende al menos un grupo hidantoína. El producto peptídico puede usarse como un material de referencia para el control de calidad de los péptidos farmacéuticos, particularmente para el control de calidad de los péptidos exendina. Además, la invención se relaciona con los componentes básicos de hidantoína, con un método para fabricar tales componentes básicos y con su uso para la síntesis de los productos peptídicos.
MX2015013464A 2013-03-21 2014-03-19 Síntesis de productos peptídicos que contienen hidantoína. MX363522B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13160384 2013-03-21
PCT/EP2014/055506 WO2014147124A1 (en) 2013-03-21 2014-03-19 Synthesis of hydantoin containing peptide products

Publications (2)

Publication Number Publication Date
MX2015013464A MX2015013464A (es) 2016-06-21
MX363522B true MX363522B (es) 2019-03-26

Family

ID=47900954

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013464A MX363522B (es) 2013-03-21 2014-03-19 Síntesis de productos peptídicos que contienen hidantoína.

Country Status (11)

Country Link
US (1) US10087221B2 (es)
EP (1) EP2976331B1 (es)
CN (1) CN105189465B (es)
AU (1) AU2014234400B2 (es)
CA (1) CA2907454C (es)
ES (1) ES2623979T3 (es)
HK (1) HK1219477A1 (es)
HU (1) HUE034308T2 (es)
MX (1) MX363522B (es)
SG (1) SG11201506804VA (es)
WO (1) WO2014147124A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201791289A1 (ru) 2014-12-11 2017-12-29 Президент Энд Феллоуз Оф Гарвард Колледж Ингибиторы клеточного некроза и связанные с ними способы
CN106928340A (zh) * 2015-12-31 2017-07-07 深圳翰宇药业股份有限公司 一种利西拉来的制备方法

Family Cites Families (223)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3906031A (en) 1971-03-15 1975-09-16 Research Corp Novel 9-fluorenylmethoxycarbonyl compounds
US3835175A (en) 1971-03-15 1974-09-10 Research Corp 9-fluorenylmethanol haloformates, carbonates and thiocarbonates
US4108846A (en) 1977-02-01 1978-08-22 Hoffmann-La Roche Inc. Solid phase synthesis with base N alpha-protecting group cleavage
DE3542442A1 (de) 1985-11-30 1987-06-04 Hoechst Ag Verfahren zur herstellung von peptiden unter der verwendung von perchloraten
US5175254A (en) 1988-09-24 1992-12-29 Societe D'expansion Scientifque Expansia Solid phase peptide synthesis using a polyacrylic support in aqueous solution
GB8913089D0 (en) 1989-06-07 1989-07-26 Ciba Geigy Japan Ltd Novel endothelin derivative
US5352796A (en) 1989-10-30 1994-10-04 The Salk Institute For Biological Studies Amino acids useful in making GnRH analogs
US5580957A (en) 1989-10-30 1996-12-03 The Salk Institute For Biological Studies GnRH analogs
US5296468A (en) 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
US5169932A (en) 1989-10-30 1992-12-08 The Salk Institute For Biological Studies Gnrh analogs
EP0445801A3 (en) 1990-03-08 1992-07-01 Kuraray Co., Ltd. Peptide and its use
IT1241395B (it) 1990-04-02 1994-01-10 Eniricerche Spa Composti immunogenici,il procedimento per la loro sintesi e loro impiego per la preparazione di vaccini antimalaria
DE4014655A1 (de) 1990-05-08 1991-11-14 Behringwerke Ag Peptidamide, verfahren zu deren herstellung und diese enthaltende mittel als fibrin/thrombin-gerinnungsinhibitoren
TW295589B (es) 1990-08-30 1997-01-11 Hoechst Ag
US6040423A (en) 1990-08-31 2000-03-21 Gsellschaft Fur Biotechnologische Forschung Mbh (Gbf) Process for synthesis of peptides
US5744450A (en) 1991-03-14 1998-04-28 The Salk Institute For Biological Studies GnRH analogs
IL101074A (en) 1991-03-14 1997-09-30 Salk Inst For Biological Studi GnRH ANALOGS AND THEIR PREPARATION
US5576296A (en) 1991-05-15 1996-11-19 Aktiebolaget Astra Galanin antagonist
SE9101472D0 (sv) 1991-05-15 1991-05-15 Trion Forskning & Utveckling Galanin antagonist
GB9112825D0 (en) 1991-06-14 1991-07-31 Ici Plc Process for making peptides
DE69225597T2 (de) 1991-08-09 1998-11-26 Kolbeck, Winfried, 81247 Muenchen Peptide mit einer lanthionin-brücke
US6028168A (en) 1991-08-09 2000-02-22 Winfried Kolbeck Lanthionine bridged peptides
CA2118806A1 (en) 1991-09-18 1993-04-01 William J. Dower Method of synthesizing diverse collections of oligomers
US5639603A (en) 1991-09-18 1997-06-17 Affymax Technologies N.V. Synthesizing and screening molecular diversity
AU3914393A (en) 1991-12-18 1994-03-15 Board Of Regents Of The University Of Oklahoma, The Peptide inhibitors of inflammation mediated by selectins
BR9305435A (pt) 1992-03-06 1994-12-27 Innogenetics Nv Processo para determinação de peptídeos correspondendo a epítopos imunologicamente importantes e seu uso em um processo para determinação de anticorpos ou peptídeos biotinilados correspondendo a epítopos imunologicamente importantes, processo para preparação dos mesmos e composições contendo os mesmos
US6709828B1 (en) 1992-03-06 2004-03-23 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
US6667387B1 (en) 1996-09-30 2003-12-23 N.V. Innogenetics S.A. HCV core peptides
EP0656904A1 (en) 1992-05-28 1995-06-14 Centocor Inc. Peptide inhibitors of selectin binding
US5516891A (en) 1992-06-16 1996-05-14 Kinerton, Ltd. Liquid phase synthesis of peptides and peptide derivatives
IE921942A1 (en) 1992-06-16 1993-12-29 Gary A Siwruk John S Eynon Liquid phase synthesis of peptides and peptide derivatives
WO1994005314A1 (en) 1992-09-08 1994-03-17 Centocor, Inc. Peptide inhibitors of leukocyte adhesion
US5563032A (en) 1992-10-21 1996-10-08 The United States Of America As Represented By The Department Of Health And Human Services Mosaic polypeptide and methods for detecting the hepatitis E virus
US5736315A (en) 1992-10-21 1998-04-07 National Institute Of Health Methods and compositions for detecting anti-hepatitis E virus activity
WO1994014836A1 (en) 1992-12-18 1994-07-07 Centocor, Inc. Peptide inhibitors of selectin binding
DE4244565A1 (de) 1992-12-30 1994-07-07 Forssmann Wolf Georg Verfahren und Anwendung des LPAP (Lymphocytoma Proliferation Activating Peptide
ES2133428T3 (es) 1993-02-19 1999-09-16 Hoffmann La Roche Fabricacion de amidas y peptidos, exenta de racemizacion, en presencia de cantidades cataliticas de un compuesto n-hidroxi.
JPH06256384A (ja) 1993-02-26 1994-09-13 Shimadzu Corp クリーベイジ装置
GB9319776D0 (en) 1993-09-24 1993-11-10 Medical Res Council Azapeptide synthesis
US5503805A (en) 1993-11-02 1996-04-02 Affymax Technologies N.V. Apparatus and method for parallel coupling reactions
US6165778A (en) 1993-11-02 2000-12-26 Affymax Technologies N.V. Reaction vessel agitation apparatus
WO1995012608A1 (en) 1993-11-02 1995-05-11 Affymax Technologies N.V. Synthesizing and screening molecular diversity
WO1995014787A1 (en) 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
DE4341471A1 (de) 1993-12-02 1995-06-08 Schering Ag Tumor-Nekrose-Faktor-alpha-inaktivierende CDR-Peptide
US5502165A (en) 1994-04-04 1996-03-26 Merck & Co., Inc. Process for peptide segment condensation
US5614608A (en) 1995-01-20 1997-03-25 Selectide Corporation Apparatus and method for multiple synthesis of organic compounds on polymer support
EP0822939A1 (en) 1995-04-28 1998-02-11 Takeda Chemical Industries, Ltd. Cyclic pentapeptide lh-rh receptor antagonists
GB9511474D0 (en) 1995-06-07 1995-08-02 Ciba Geigy Ag Antiviral peptoid compounds
DE19534988A1 (de) 1995-09-21 1997-03-27 Forssmann Wolf Georg Verfahren zur Herstellung und Anwendung synthetischer, biotinylierter Peptide
DE19543628A1 (de) 1995-11-24 1997-05-28 Forssmann Wolf Georg Humanes, im Blut zirkulierendes Peptid mit insulinotroper Wirkung (GCAP-II-(89-112), (Guanylyl Cyclase C Aktivierendes Peptid II) und seine GCAP-Analoga, insbesondere das GCAP-I-(99-115), seine Anwendung als pharmakologischer Wirkstoff und Benutzung seines Wirkungsprinzipes zur Bereitstellung neuer GC-C-abhängiger insulinotroper Wirkstoffe
TW505654B (en) 1996-07-30 2002-10-11 Hoffmann La Roche Synthesis of analogs of PTH and PTHrP
EP0932614A1 (en) 1996-09-09 1999-08-04 Zealand Pharmaceuticals A/S Peptide prodrugs containing an alpha-hydroxyacid linker
WO1998011125A1 (en) 1996-09-09 1998-03-19 Zealand Pharmaceuticals A/S Improved solid-phase peptide synthesis and agent for use in such synthesis
US7176282B1 (en) 1996-09-09 2007-02-13 Zealand Pharma A/S Solid-phase peptide synthesis and agent for use in such synthesis
ES2234095T3 (es) 1997-01-21 2005-06-16 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Fragmento de proteasa iga1 como peptido de soporte.
NZ506839A (en) 1998-03-09 2003-05-30 Zealand Pharma As Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
JP3786533B2 (ja) 1998-11-12 2006-06-14 善彦 西村 ペプチド及び骨形成促進剤
PT1144011E (pt) 1998-12-11 2010-06-16 Coulter Pharm Inc Compostos pró-fármacos e processo para a sua preparação
US7425541B2 (en) 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
FR2792631B1 (fr) 1999-04-21 2004-03-19 Pasteur Institut Support solide fonctionnalise pour la synthese de composes comportant au moins une fonction alpha oxoaldehyde et ses applications.
US6469136B1 (en) 1999-07-07 2002-10-22 Trimeris, Inc. Methods and composition for peptide synthesis
US6703480B1 (en) 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
FR2803594B1 (fr) 2000-01-11 2002-07-19 Centre Nat Rech Scient Oligomeres de mimes contraints non peptidiques de dipeptides ou de tripeptides, et leurs utilisations
KR20020073184A (ko) 2000-01-27 2002-09-19 일라이 릴리 앤드 캄파니 글루카곤 유사 펩티드 1 화합물을 용해시키는 방법
US6476186B1 (en) 2000-05-23 2002-11-05 Institute Of Nuclear Energy Research Process for preparing octreotide and derivatives thereof
AU2001271301B2 (en) 2000-06-14 2006-08-31 Medarex, Inc. Prodrug compounds cleavable by thimet oligopeptidase
US20020058788A1 (en) 2000-08-25 2002-05-16 Sheppeck James E. Facile deprotection of Fmoc protected amino groups
NO314588B1 (no) 2000-09-04 2003-04-14 Bionor Immuno As HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV
WO2002040512A2 (de) 2000-11-14 2002-05-23 Ipf Pharmaceuticals Gmbh Humanes beta-defensin-3
DK1263800T3 (da) 2001-01-04 2007-03-19 Council Scient Ind Res Linker-baseret fast understötning tl peptidsyntese og lille-molekyle organisk syntese
GB0105069D0 (en) 2001-03-01 2001-04-18 Univ Ulster The Modified peptide
US20090281032A1 (en) 2001-03-01 2009-11-12 Peter Raymond Flatt Modified CCK peptides
BR0101088A (pt) 2001-03-19 2003-03-18 Biolab Sanus Farmaceutica Ltda Processo de isolamento e purificação de peptìdeos inibidores das vasopeptidases, com especificidade para o sìtio carboxìlico da enzima conversora da angiotensina, secretados pelas glândulas do veneno de serpentes (bpps), particularmente bothrops jararaca, ou produzidos endogenamente (evasins) possuindo ação vasodilatadora e anti-hipertensiva; processo de determinação da sequência de amido-ácidos dos peptìdios inibidores secretados pela glândula de veneno de serpentes (bpps) ou endógenos (evasins); processo de determinação da sequência de aminoácidos dos bpps por dedução do cdna dos precursores dessas moléculas expressos em tecidos de serpentes, especificamente bothrops jararaca. processo de determinação da sequência de aminoácidos dos evasins por dedução do cdna dos precursores dessas moléculas expressos em tecidos de serpentes, especificamente bothrops jararaca, processo de amplificação do cdna a partir das bibliotecas de cdna de pâncreas e/ou cérebro de serpentes, especificamente bothrops jararaca; processo de sìntese em fase sólida de peptìdeos inibidores das vasopeptidases com ação vasodilatadora e anti-hipertensiva, peptìdeos inibidores das vasopeptidases com ação anti-hipertensiva; utilização dos peptìdeos inibidores das vaso peptidases com ação vasodilatadora e anti-hipertensiva na obtenção de composições farmacêuticas; processo de determinação da atividade inibitória sobre as vasopeptidases e de atividade biológica sobre músculo liso, sistema cardiovascular e microcirculatório.
WO2002083606A1 (en) 2001-04-17 2002-10-24 University Of Alberta A linker system for the synthesis and screening of combinatorial libraries of polyamine derivatives on water compatible supports
CN1162446C (zh) 2001-05-10 2004-08-18 上海华谊生物技术有限公司 促胰岛素分泌肽衍生物
FR2825095B1 (fr) 2001-05-28 2003-09-26 Dev Des Antigenes Combinatoire Dispositif de presentation de polypeptides, utilisable comme "puce" pour la detection miniaturisee de molecules
US20030138880A1 (en) 2001-08-24 2003-07-24 University Of British Columbia Solid-phase synthesis of oligosaccharides and glycopeptides using glycosynthases
US7138489B2 (en) 2002-04-11 2006-11-21 Daiichi Asubio Pharma Co., Ltd. Method for producing a modified peptide
US6809190B2 (en) 2002-04-24 2004-10-26 Credia Japan Co., Ltd. Functional peptide nucleic acid and its production method
EP1504022B1 (en) 2002-05-03 2006-10-11 Avecia Limited Process for the synthesis of peptide amides by side-chain attachment to a solid phase
GB0210183D0 (en) 2002-05-03 2002-06-12 Avecia Ltd Process
GB0210185D0 (en) 2002-05-03 2002-06-12 Avecia Ltd Process
PL374438A1 (en) 2002-05-10 2005-10-17 Pharmacia Corporation Peptide compounds and their use as protease substrates
ES2195787B1 (es) 2002-05-20 2005-06-01 Diverdrugs, S.L. Compuestos capaces de bloquear la respuesta a sustancias quimicas o estimulos termicos o mediadores de la inflamacion de los nociceptores, un metodo para su obtencion y composiciones que los continen.
WO2004018502A1 (en) 2002-08-09 2004-03-04 Yamanouchi Europe B.V. Compounds binding to p-selectin
DE60330182D1 (de) 2002-09-08 2009-12-31 Applera Corp Festphasengebundene PNA-Dimere und deren Synthese
WO2004035623A2 (en) 2002-10-02 2004-04-29 Zealand Pharma A/S Stabilized exendin-4 compounds
EP1445260A1 (de) 2003-02-04 2004-08-11 Jerini AG Verfahren zur Immobilisierung von chemischen Verbindungen an Festphasen
BRPI0408978B8 (pt) 2003-04-08 2021-07-27 Novo Nordisk As processos para regenerar uma fase estacionária cromatográfica
MX287895B (es) 2003-04-08 2011-06-30 Novo Nordisk As Regeneracion de fases estacionarias cromatograficas.
EP1614750A4 (en) 2003-04-15 2006-09-20 Credia Japan Co Ltd NOVEL FUNCTIONAL PEPTIDE NUCLEIC ACID AND PROCESS FOR PRODUCING THE SAME
EP1631597A4 (en) 2003-05-22 2007-07-11 Gryphon Therapeutics Inc SOLID PHASE CHEMICAL LIGATION CARRIED OUT WITH A MOBILE BONDING AGENT
EP1633391B1 (en) 2003-06-03 2011-10-19 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
US7414106B2 (en) 2003-06-19 2008-08-19 Lawrence Livermore National Security, Llc Synthesis of peptide α-thioesters
US7393920B2 (en) 2003-06-23 2008-07-01 Cem Corporation Microwave-assisted peptide synthesis
US7902488B2 (en) 2003-06-23 2011-03-08 Cem Corporation Microwave-assisted peptide synthesis
JP2007526235A (ja) 2003-08-21 2007-09-13 ノボ　ノルディスク　アクティーゼルスカブ グルカゴン様ペプチドの精製
ATE376556T1 (de) 2003-12-31 2007-11-15 Hoffmann La Roche Verfahren zur peptidsynthese unter verwendung einer reduzierten menge an entschützungsmittel
FR2864830B1 (fr) 2004-01-06 2006-03-10 Centre Nat Rech Scient Procede de synthese sur support solide de composes peptidiques, notamment de composes peptidiques comportant un residu arginine
US20070244041A1 (en) 2004-02-23 2007-10-18 Reoscience A/S Peptide Yy Analogues
CA2458084A1 (en) 2004-03-12 2005-09-12 Dalton Chemical Laboratories Inc. Novel process for octreotide synthesis
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
DK1771463T3 (da) 2004-07-16 2008-04-21 Lonza Ag Fremgangsmåde til peptidsyntese
WO2006040037A1 (en) 2004-10-12 2006-04-20 F. Hoffmann-La Roche Ag Solid phase peptide sythesis
US8435800B2 (en) 2004-11-22 2013-05-07 Biosight Ltd. Activated labeling reagents and methods for preparing and using the same
WO2006127048A2 (en) 2004-12-17 2006-11-30 Kansas State University Research Foundation NOVEL pH DEPENDENT ADHESIVE PEPTIDES
ES2541633T3 (es) 2005-01-14 2015-07-22 Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. Exendinas modificadas y usos de las mismas
US8716221B2 (en) 2005-01-14 2014-05-06 Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. Modified exendins and uses thereof
JP2008534639A (ja) 2005-04-08 2008-08-28 ロンザ ア−ゲ− Ｐｅｇ樹脂上におけるアルファ−ヘリックスのペプチド合成
AU2006243344B2 (en) 2005-05-04 2011-04-21 Lonza Ag Solid phase bound thymosin alpha-1 and its synthesis
CN1298732C (zh) 2005-05-17 2007-02-07 南京工业大学 多肽微波固相合成法
MX2007014819A (es) 2005-05-26 2008-02-14 Squibb Bristol Myers Co Moduladores del receptor glp-1 n-terminalmente modificados.
EP1805204A2 (en) 2005-09-14 2007-07-11 Novetide Ltd. Process for production of bivalirudin
US8202837B2 (en) 2005-11-04 2012-06-19 Glaxosmithkline Llc Methods for administering hypoglycemic agents
CN100374462C (zh) 2005-11-21 2008-03-12 大连帝恩生物工程有限公司 截短胰高血糖素样肽1(sGLP-1)、制法及其应用
JP2009518345A (ja) 2005-12-07 2009-05-07 テフニーシェ ウニヴェルジテート ミュンヘン 因子ｖｉｉｉおよび因子ｖｉｉｉ様タンパク質に対する小型ペプチドおよびペプチド模倣物の親和性リガンド
AU2006326256B2 (en) * 2005-12-14 2011-11-03 Medivir Ab (2,5-dioxoimidazolidin-I-yl)-N-hydroxy-acetamides as metalloproteinase inhibitors
AU2007232742B2 (en) 2006-03-29 2012-02-02 Glytech, Inc. Method for production of peptide thioester compound
ES2283212B1 (es) 2006-03-31 2008-08-16 Lipotec S.A. Peptidos sinteticos utiles en el tratamiento de la piel y su uso en composiciones cosmeticas o dermofarmaceuticas.
US20070231258A1 (en) 2006-03-31 2007-10-04 Karyon Ctt Ltd. Peptide conjugates
US20100022457A1 (en) 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
GB2440388A (en) 2006-06-30 2008-01-30 Ucl Biomedica Plc Methods of linking a carbohydrate or polyalkylene oxide to a protein, precursors and the resultant products
WO2008028974A1 (en) 2006-09-08 2008-03-13 Novo Nordisk A/S Methods of optimizing chromatographic separation of polypeptides
WO2008044890A1 (en) 2006-10-12 2008-04-17 Dong Kook Pharm. Co., Ltd A method for preparing peptides using by solid phase synthesis
ES2322882B1 (es) 2006-10-25 2010-04-22 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal.
EP1923397B1 (en) 2006-11-14 2009-10-28 NERVIANO MEDICAL SCIENCES S.r.l. Fluorinated amino acids and peptides
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
AU2007333846B2 (en) 2006-12-14 2014-01-23 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
US7981998B2 (en) 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
EP2111414B1 (en) 2007-02-15 2014-07-02 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
US20080287650A1 (en) 2007-03-01 2008-11-20 Avi Tovi High purity peptides
WO2008137165A1 (en) 2007-05-07 2008-11-13 President And Fellows Of Harvard College Anti-glycated cd59 antibodies and uses thereof
EP2158214B1 (en) 2007-06-15 2011-08-17 Zealand Pharma A/S Glucagon analogues
WO2009003666A1 (en) 2007-06-29 2009-01-08 Lonza Ag Process for the production of pramlintide
CN101357938B (zh) 2007-07-31 2013-07-03 周逸明 固相多肽合成Exenatide的制备方法
CN101357937B (zh) 2007-07-31 2012-11-07 上海苏豪逸明制药有限公司 固相多肽合成阿托西般的制备方法
JP2011506376A (ja) 2007-12-11 2011-03-03 エフ．ホフマン−ラ ロシュ アーゲー 固相及び溶液相の組み合わせ技術を使用したインシュリン分泌性ペプチド合成
US20100317827A1 (en) 2008-02-06 2010-12-16 Biocon Limited Method of Purifying a Peptide
ES2330291B1 (es) 2008-02-29 2010-10-18 Lipotec Sa Peptidos utiles en el tratamiento de la piel, mucosas y/o cuero cabelludo y su uso en composiciones cosmeticas o farmaceuticas.
CN101525368B (zh) 2008-03-06 2012-05-30 海南建邦制药科技有限公司 一种多肽合成脱保护剂
CN101525370A (zh) 2008-03-06 2009-09-09 海南建邦制药科技有限公司 一种新型高效多肽合成缩合剂
CN101255191A (zh) 2008-03-12 2008-09-03 中国药科大学 微波促进固相合成胰高血糖素样肽-1(glp-1)类似物及其应用
WO2009132231A2 (en) 2008-04-24 2009-10-29 Therimunex Pharmaceuticals, Inc. Peptidyl diacylglycerides
US20120149868A1 (en) 2008-05-15 2012-06-14 Novo Nordisk A/S Purification of peptides prepared by solid phase synthesis
CA2729296A1 (en) 2008-06-17 2010-01-28 Richard D. Dimarchi Gip-based mixed agonists for treatment of metabolic disorders and obesity
NZ589847A (en) 2008-06-17 2013-01-25 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
WO2010028122A1 (en) 2008-09-03 2010-03-11 Scinopharm Taiwan Ltd. Process for making bivalirudin
TW201012829A (en) 2008-09-22 2010-04-01 Ipsen Mfg Ireland Ltd Process for the synthesis of (Aib8,35)hGLP-1(7-36)-NH2
US9206223B2 (en) 2008-09-22 2015-12-08 Aileron Therapeutics, Inc. Methods for preparing purified polypeptide compositions
EP2794663A1 (en) 2008-12-05 2014-10-29 Angiochem Inc. Peptide therapeutic conjugates and uses thereof
BRPI0922689A2 (pt) 2008-12-05 2018-11-06 Angiochem Inc. conjugados de neurotensina ou análogos de neurotensina e usos dos mesmos
JP2012510797A (ja) 2008-12-05 2012-05-17 アンジオケム インコーポレーテッド レプチンおよびレプチン類似体コンジュゲートならびにそれらの使用
EA020537B1 (ru) 2008-12-15 2014-11-28 Зилэнд Фарма А/С Аналоги глюкагона
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
ES2477880T3 (es) 2008-12-15 2014-07-18 Zealand Pharma A/S Análogos del glucagón
JP5635532B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
CN101463078B (zh) 2009-01-12 2011-07-27 华东师范大学 一种Exendin-4衍生物及其固相化学合成
CN101463081B (zh) 2009-01-12 2012-07-04 华东师范大学 一种glp-1衍生物
CN101538324B (zh) 2009-01-13 2013-01-16 深圳翰宇药业股份有限公司 一种制备艾塞那肽的方法
ES2349972B1 (es) 2009-02-16 2011-11-24 Lipotec, S.A. Péptidos útiles en el tratamiento y/o cuidado de la piel, mucosas y/o cuero cabelludo y su uso en composiciones cosméticas o farmacéuticas.
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
CN102395598B (zh) 2009-04-17 2014-07-30 利普泰股份公司 用于治疗和/或护理皮肤和/或毛发的肽、及其在化妆用组合物或药物组合物中的用途
CN101555274B (zh) 2009-05-15 2013-08-21 海南双成药业股份有限公司 一种多肽固相合成比法卢定粗品的制备方法
PE20120914A1 (es) 2009-06-16 2012-08-22 Univ Indiana Res & Tech Corp Compuestos glucagon activo de receptor de gip
NZ597981A (en) 2009-07-13 2014-02-28 Zealand Pharma As Acylated glucagon analogues
US8946166B2 (en) 2009-07-24 2015-02-03 Lipotec, S.A. Peptide-based compounds and compositions which inhibit muscle contraction
CN101987865B (zh) * 2009-07-29 2014-07-30 中国人民解放军军事医学科学院毒物药物研究所 含有乙内酰脲结构的促黄体生成素释放激素拮抗剂
ES2358829B1 (es) 2009-10-23 2012-06-25 Lipotec, S.A. Péptidos útiles en el tratamiento y/o cuidado de la piel, mucosas y/o cabello y su uso en composiciones cosméticas o farmacéuticas.
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
EP2528618A4 (en) 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
WO2011107447A1 (en) 2010-03-01 2011-09-09 Novo Nordisk A/S Preparative rp-hplc method for purifying peptides
US20130035285A1 (en) 2010-03-26 2013-02-07 Novo Nordisk A/S Novel glucagon analogues
US8620595B2 (en) 2010-03-26 2013-12-31 University Of Manitoba Methods for determining the retention of peptides in reverse phase chromatography using linear solvent strength theory
AR080592A1 (es) 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
CN102918177B (zh) 2010-05-31 2015-09-09 株式会社捷太格特 覆盖部件的制造方法
EP2579435B1 (en) 2010-06-01 2016-11-30 Honda Motor Co., Ltd. Controller for dc/dc converter
US20110313131A1 (en) 2010-06-21 2011-12-22 Christelle Carl Reversed phase hplc purification of a glp-1 analogue
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
CN101906150B (zh) 2010-06-28 2013-01-09 上海昂博生物技术有限公司 一种比法卢定的制备方法
WO2012057624A1 (en) 2010-10-25 2012-05-03 Pepscan Systems B.V. Novel bicyclic peptide mimetics
EP2632936A1 (en) 2010-10-29 2013-09-04 Lonza Ltd Diketopiperazine forming dipeptidyl linker
EP2654773B1 (en) 2010-12-22 2018-10-03 Indiana University Research and Technology Corporation Glucagon analogs exhibiting gip receptor activity
US9290537B2 (en) 2010-12-23 2016-03-22 Universiteit Gent Method for cross-linking peptides
CN102643339B (zh) 2011-02-21 2014-04-09 天津药物研究院 一种glp-1类似物、制备方法及其应用
CN102174082B (zh) 2011-02-23 2014-08-27 上海昂博生物技术有限公司 一种艾塞那肽的制备方法
ES2397889B1 (es) 2011-03-25 2014-02-07 Lipotec, S.A. PÉPTIDOS MODULADORES DE PGC-1Alfa.
CN102718858B (zh) 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
DK2694095T3 (en) 2011-04-05 2018-05-28 Longevity Biotech Inc COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME
CN102786590A (zh) 2011-05-19 2012-11-21 江苏豪森药业股份有限公司 分枝型peg修饰的glp-1类似物及其可药用盐
US8933196B2 (en) 2011-05-20 2015-01-13 National Central University Peptide chromatographic purification assisted by combining of solubility parameter and solution conformation energy calculations
CN102286076B (zh) 2011-06-23 2014-03-12 成都圣诺科技发展有限公司 比伐卢定的制备方法
CN102286092B (zh) 2011-09-14 2014-01-01 深圳翰宇药业股份有限公司 利拉鲁肽的固相合成方法
NL2007536C2 (en) 2011-10-05 2013-04-08 Academisch Ziekenhuis Leiden Lumc Adjuvant compound.
MX350536B (es) 2011-12-23 2017-09-08 Ipsen Mfg Ireland Limited Proceso para la sintesis de peptidos terapeuticos.
CN103242443A (zh) 2012-02-06 2013-08-14 长春百克生物科技股份公司 一种胸腺素α1及其类似物的制备方法
CN102584944B (zh) 2012-02-06 2014-12-17 成都圣诺生物科技股份有限公司 一种依非巴特的制备方法
CN102584982B (zh) 2012-02-10 2014-02-05 深圳翰宇药业股份有限公司 一种纯化固相合成利拉鲁肽粗肽的方法
CN102558338B (zh) 2012-02-10 2014-09-17 深圳翰宇药业股份有限公司 一种合成利西拉来的方法
WO2013156493A1 (en) 2012-04-16 2013-10-24 Lipotec S.A. Compounds for the treatment and/or care of the skin and/or mucous membranes and their use in cosmetic or pharmaceutical compositions
US20130289241A1 (en) 2012-04-26 2013-10-31 Shanghai Ambiopharm, Inc. Method for preparing exenatide
US9850471B2 (en) 2012-05-16 2017-12-26 Noxxon Pharma Ag Enzymatic synthesis of L-nucleic acids
CN102875663B (zh) 2012-09-26 2014-06-11 深圳翰宇药业股份有限公司 利西拉来的纯化方法
CA2899387C (en) 2013-01-29 2018-07-17 Neuland Health Sciences Private Limited Purification of organic compounds using surrogate stationary phases on reversed phase columns
CN103965285B (zh) 2013-02-06 2016-12-28 北京大学 一种以超顺磁纳米颗粒为固相进行多肽合成及同步构建多肽磁纳米探针的方法
CN103333237B (zh) 2013-05-07 2015-03-11 海南双成药业股份有限公司 一种固相片段法合成艾塞那肽
CA2918221A1 (en) 2013-07-15 2015-01-22 North Carolina State University Protease-resistant peptide ligands
US9263194B2 (en) 2013-09-06 2016-02-16 Gwangju Institute Of Science And Technology Porphyrin-peptoid conjugate and the preparation process thereof
WO2015038919A1 (en) 2013-09-15 2015-03-19 Stc. Unm Method for atomic layer deposition
CN103536912B (zh) 2013-09-30 2015-05-13 重庆理工大学 一种猪圆环病毒2型表位肽疫苗及其制备方法
CN103613655B (zh) 2013-11-20 2015-05-13 陕西东大生化科技有限责任公司 一种低成本纯化艾塞那肽的方法
CA2931694C (en) 2013-12-01 2020-12-01 University Of Copenhagen Fatty acid derivatives of dimeric peptide ligands of psd-95 and use thereof for treating excitotoxic disease
HU230584B1 (hu) 2014-02-28 2017-01-30 Szegedi Tudományegyetem Eljárás peptidek előállítására
CN104086631A (zh) 2014-07-10 2014-10-08 成都天台山制药有限公司 卡贝缩宫素和制法
CN104211801A (zh) 2014-07-25 2014-12-17 杭州诺泰制药技术有限公司 一种制备利西拉来的方法
WO2016020349A1 (en) 2014-08-07 2016-02-11 F. Hoffmann-La Roche Ag Processes for the preparation of oxytocin analogues
JP6574257B2 (ja) 2014-10-07 2019-09-11 アン アンド ロバート エイチ． ルーリー チルドレンズ ホスピタル オブ シカゴ 新規の抗Ｎｏｄａｌ抗体及びその使用方法
CN105585612B (zh) 2014-10-20 2020-05-05 北京益生康华医药技术有限公司 八肽修饰的地塞米松、制备、纳米结构和应用
WO2016067271A1 (en) 2014-10-31 2016-05-06 Auro Peptides Ltd A process for the preparation of liraglutide
WO2016084100A2 (en) 2014-11-26 2016-06-02 Alaparthi Lakshmi Prasad Novel and efficient method for large scale synthesis of romidepsin
US10308677B2 (en) 2014-12-19 2019-06-04 Cem Corporation Coupling method for peptide synthesis at elevated temperatures
CN105111303B (zh) 2015-06-23 2019-07-26 济南康和医药科技有限公司 一种固液结合制备利拉鲁肽的方法
CA3018627A1 (en) 2016-03-23 2017-09-28 Bachem Holding Ag Purification of glucagon-like peptide 1 analogs

Also Published As

Publication number Publication date
EP2976331A1 (en) 2016-01-27
SG11201506804VA (en) 2015-09-29
HK1219477A1 (zh) 2017-04-07
CA2907454C (en) 2021-05-04
AU2014234400A1 (en) 2015-10-01
CA2907454A1 (en) 2014-09-25
CN105189465A (zh) 2015-12-23
US10087221B2 (en) 2018-10-02
ES2623979T3 (es) 2017-07-12
MX2015013464A (es) 2016-06-21
AU2014234400B2 (en) 2017-11-16
WO2014147124A1 (en) 2014-09-25
HUE034308T2 (en) 2018-02-28
US20160289282A1 (en) 2016-10-06
CN105189465B (zh) 2019-02-26
EP2976331B1 (en) 2017-03-01

Similar Documents

Publication Publication Date Title
ZA201707233B (en) Gas fermentation for the production of protein or feed
MX340558B (es) Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro.
PH12014502010A1 (en) Bispecific antibodies against human tweak and human il17 and uses thereof
MX2016004940A (es) Proceso para la preparacion de compuestos plaguicidas.
NZ702752A (en) Methods for synthesizing amatoxin building block and amatoxins
DK2377900T3 (da) Proces til at tilberede overflademodificeret mineralmateriale, deraf følgende produkter og anvendelser
MX2022014578A (es) Metodo para producir material aislante o un producto aislante para la industria de materiales refractarios, materiales y productos aislantes correspondientes, y sus usos.
WO2015121379A3 (en) Process for producing vanillin
EP3369479A4 (en) ADSORBENT MATERIAL FOR MULTIPLE PATHOGENIC SEPTICEMIA FACTORS, AS WELL AS PREPARATION METHOD AND APPLICATION THEREOF
WO2016033437A3 (en) Polyethers, polyamines, polythioethers, and methods for making same
EP3633771A4 (en) GRAPHENE COATED POWDER MATERIAL PREPARATION PROCESS AND PROCESS PRODUCT
EP3640258A4 (en) NEW POLYPEPTIDE AND PROCESS FOR MANUFACTURING A PRODUCT BASED ON ORNITHIN WITH IT
MX2017015137A (es) Composicion farmaceutica oral de dosis diaria de isotretinoin.
EP3321242A4 (en) CEMENT ADDITIVE, CEMENT COMPOSITION, CEMENT ADDITIVE RAW MATERIAL
MX351521B (es) Composición farmacéutica que comprende fimasartan e hidroclorotiazida.
EP3816231A4 (en) POLYAMIDE RESIN COMPOSITION FOR BLOW MOLDED PRODUCTS EXPOSED TO HIGH PRESSURE HYDROGEN, AND BLOW MOLDED PRODUCT
EP3263573A4 (en) Crystal of imidazo-oxazine, pharmaceutical composition containing said crystal, and method for producing said crystal
EP3229791A4 (en) Novel polymorphs of ivacaftor, process for its preparation and pharmaceutical composition thereof
HK1205999A1 (en) Process for the preparation of cement, mortars, concrete compositions containing calcium carbonate - based filler(s) (pre) - treated with ultrafine (uf) filler(s), compositions and cement products obtained and their applications (uf)()
MX2018003707A (es) Producto de superficie solida y su proceso de fabricacion.
PL3355870T3 (pl) Sposób wytwarzania kompresowanych tabletek
EP3725792A4 (en) PREPARATION FOR THE NATURAL PRODUCT TRABECTEDIN
EP3488876B8 (en) Novel formula for synthesizing bone replacement material, and manufacturing method and application method thereof
EP3728418A4 (en) IMPROVED COMPOSITE PRODUCTION PROCESS
MX2015013464A (es) Sintesis de productos peptidicos que contienen hidantoina.